Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.44 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757679 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL226510 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL2517959 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4794837 | 1.00 | LPAR1 (0.58) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL1081182 | 0.90 | ALDH1A1 (0.53) | LPAR1LPAR3LPAR2 | |
| SCHEMBL303128 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4204833 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL8636551 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4879843 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4294185 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642320-B2 | Nanoparticulate prodrugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-05-09 | — | — | US | disclosed |
| EP-3515415-B1 | NANOPARTICULATE PRODRUGS | CENTRE NAT RECH SCIENT (FR) | 2021-12-29 | — | — | EP | disclosed |
| US-20210275462-A1 | NANOPARTICULATE PRODRUGS | Universite Paris-Saclay (FR) | 2021-09-09 | — | — | US | disclosed |
| US-10660883-B2 | Inhalable nicotine formulations, and methods of making and using thereof | PHILIP MORRIS PRODUCTS S.A. (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| EP-3515415-A1 | NANOPARTICULATE PRODRUGS | Centre National De La Recherche Scientifique (FR) | 2019-07-31 | — | — | EP | disclosed |
| US-20190105316-A1 | Inhalable Nicotine Formulations, and Methods of Making and Using Thereof | NICO PUFF CORPORATION (CA) | 2019-04-11 | — | — | US | disclosed |
| US-10149844-B2 | Inhalable nicotine formulations, and methods of making and using thereof | PHILIP MORRIS PRODUCTS S.A. (CH) | 2018-12-11 | — | — | US | disclosed |
| WO-2018163085-A1 | INHALABLE NICOTINE FORMULATIONS, AND METHODS OF MAKING AND USING THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2018-09-13 | — | — | WO | disclosed |
| US-20070178166-A1 | PROCESSES FOR MAKING PARTICLE-BASED PHARMACEUTICAL FORMULATIONS FOR PULMONARY OR NASAL ADMINISTRATION | ACUSPHERE, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1796653-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060147520-A1 | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | COTHERIX, INC. | 2006-07-06 | — | — | US | disclosed |
| EP-1667659-A1 | INJECTABLE, ORAL, OR TOPICAL SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS | Acusphere, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006014930-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | COTHERIX, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1556018-A1 | SUSTAINED RELEASE POROUS MICROPARTICLES FOR INHALATION | Acusphere, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005032523-A1 | INJECTABLE, ORAL, OR TOPICAL SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS | ACUSPHERE, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050069591-A1 | Injectable, oral, or topical sustained release pharmaceutical formulations | CEPHALON, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040105821-A1 | Sustained release pharmaceutical formulation for inhalation | CEPHALON, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004030659-A1 | SUSTAINED RELEASE POROUS MICROPARTICLES FOR INHALATION | ACUSPHERE, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, MRPS18A | LPAR1 1534/4885LPAR3 2800/4885LPAR2 2356/4885 |
| US-11642320-B2 | Nanoparticulate prodrugs | TNF, C5AR1, CYP21A2 | LPAR1 2257/4885LPAR3 1762/4885LPAR2 2822/4885 |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, COG8 | LPAR1 1962/4885LPAR3 3442/4885LPAR2 2839/4885 |
| US-20060147520-A1 | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | PTGIR, PTGIS, PTGER1 | LPAR1 476/4885LPAR3 866/4885LPAR2 378/4885 |
| US-20210275462-A1 | NANOPARTICULATE PRODRUGS | C5AR1, NR3C1, TNF | LPAR1 1936/4885LPAR3 2035/4885LPAR2 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.